This is a preview of subscription content, log in via an institution to check access.
Notes
This study was funded by Millenium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Reference
Rifkin RM, et al. Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma. PharmacoEconomics-Open : 11 Oct 2019. Available from: URL: https://doi.org/10.1007/s41669-019-00184-9
Rights and permissions
About this article
Cite this article
Oral treatment reduces burden in newly diagnosed multiple myeloma. PharmacoEcon Outcomes News 839, 29 (2019). https://doi.org/10.1007/s40274-019-6310-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6310-y